Choosing Multiple Myeloma Regimens


Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.

This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.

Hinojosa addressed considerations in choosing among DRd (daratumumab, lenalidomide, dexamethasone), VRd (bortezomib, lenalidomide, dexamethasone), and KRd (carfilzomib, lenalidomide, dexamethasone) for patients with multiple myeloma based on comorbidities and adverse effects profiles. Daratumumab’s “more benign” adverse effects make it a common upfront choice, Hinojosa said, and the decision between VRd and KRd depends on patient-specific factors such as diabetes-related peripheral neuropathy or cardiovascular history. Discussing adverse events, Hinojosa highlighted infections, thrombotic events, gastrointestinal toxicity, and skin rash, emphasizing the need for routine monitoring and pharmacist-led education to increase patient awareness. Regarding clinical considerations for dose modifications or therapy switches, Hinojosa stressed evaluating changes due to toxicities or progressive disease, considering the patient’s response history and overall risk-benefit assessment. These insights guide personalized treatment approaches for optimizing outcomes in patients with multiple myeloma.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig -
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
Video 12 - "Empowering RSV Patients: Essential Vaccine Education Resources"
Video 11 - "Unmet Needs in Prevention and Management of RSV"
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Related Content
© 2024 MJH Life Sciences

All rights reserved.